Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

The gene therapy Casgevy, which will now be offered to some patients in England, could help people live disease-free, experts ...

CASGEVY ® is a non-viral, ex vivo CRISPR/Cas9 gene-edited ... region of the BCL11A gene through a precise double-strand break. This edit results in the production of high levels of fetal hemoglobin ...

Beyond Casgevy, CRISPR Therapeutics continues to ... Moreover, the high costs associated with gene therapy production and the complex manufacturing process could further pressure profit margins ...

Right now, approximately 20 billion red blood cells are busy traveling through your blood vessels. They are delivering oxygen ...

However, instead of directly editing a faulty gene, Casgevy instead takes advantage ... where they multiply and increase the production of stable, well-functioning red cells.